赛诺菲恢复四价流感疫苗在华销售，公司称不对产品价格做调整

Core Viewpoint - Sanofi has resumed the sale of its quadrivalent influenza vaccine in China after a nine-month suspension, with the vaccine for the 2025-2026 flu season receiving approval from the Chinese drug regulatory authority [1][3]. Group 1: Vaccine Production and Sales - Sanofi paused the sales of its trivalent and quadrivalent influenza vaccines for the 2024-2025 flu season due to a decline in vaccine efficacy observed during stability assessments [3]. - The company has optimized the immunogenicity and product stability evaluation for the 2025-2026 flu season, completing pilot production of the vaccine in December 2024, with all results indicating stable efficacy [3]. Group 2: Market Dynamics and Pricing - The influenza vaccine market in China is highly competitive, with many manufacturers and a historically low vaccination rate, often remaining in single digits [3]. - Despite other manufacturers reducing prices for influenza vaccines, Sanofi has decided not to adjust the price of its quadrivalent influenza vaccine, citing factors such as exchange rates and production costs [1][3].